PEMF for Prepatellar
& Knee Bursitis.

July 2026 · 8 min read · Clinical Protocol

What Is Knee Bursitis?

Bursae are fluid-filled sacs that cushion tendons and bones at points of friction. Around the knee, four bursae are most clinically relevant:

• Prepatellar bursa — anterior to the kneecap; inflamed by repeated kneeling (domestic workers, construction laborers, tile layers, wrestlers). This is the most common knee bursitis in the Philippines.
• Infrapatellar bursa (superficial and deep) — below the kneecap, anterior to the patellar tendon; inflamed by jumping sports and activities requiring repeated knee extension.
• Suprapatellar bursa — above the kneecap, continuous with the joint capsule; inflamed by direct impact or as a secondary effect of knee osteoarthritis.
• Semimembranosus bursa (Baker's Cyst) — posterior to the knee; often secondary to intra-articular pathology (meniscus tears, OA).

Knee bursitis is categorized as septic (infectious) or non-septic (traumatic/inflammatory). PEMF is indicated for non-septic (aseptic) bursitis — chronic or subacute inflammatory bursitis that does not resolve with rest, ice, or NSAIDs.

The Philippine Occupational Context

No Philippine-specific epidemiological data on knee bursitis is currently published, but occupational structure makes it endemic. The country has an estimated 1.8–2.3 million domestic workers (kasambahay), the majority of whom perform daily tasks involving floor mopping, scrubbing, and prolonged kneeling. Construction workers (estimated 2.5 million in the formal sector alone) and tile-laying craftsmen face similar exposure. Clinicians at Philippine orthopedic and physiatry departments report prepatellar bursitis as among their top-10 most frequent outpatient knee complaints — yet the standard response remains NSAIDs, aspiration, or corticosteroid injection: the last two carry infection risk, and the first fails to modify the underlying inflammatory process.

How PEMF Addresses Bursal Inflammation

The pathophysiology of aseptic bursitis involves mast cell degranulation, histamine release, and prostaglandin-driven synovial fluid accumulation. PEMF targets this cascade at three points:

1. Mast cell stabilization — Low-frequency PEMF (8–25 Hz) modulates mast cell membrane potential, reducing histamine release and the acute inflammatory cascade that drives fluid accumulation in the bursal sac.
2. Prostaglandin E2 suppression — PEMF reduces COX-2 activity independently of pharmacological inhibition, providing anti-inflammatory effect without the GI and renal risks of chronic NSAID use.
3. Microcirculation enhancement — Improved local blood flow accelerates the reabsorption of accumulated synovial fluid within the bursa, reducing the visible swelling that often limits knee flexion.
4. Cytokine modulation — IL-1β and TNF-α suppression at the bursal membrane reduces the perpetuation of the inflammatory cycle that turns acute bursitis into a chronic condition.

These mechanisms are consistent with the broader soft-tissue inflammation evidence that underlies the PMC11914662 RCT results (36% pain reduction, 55% medication reduction, n=91, 5 orthopedic clinics).

Evidence Base

No randomized controlled trial has been published specifically for prepatellar or infrapatellar bursitis treated with PEMF — honest framing is essential for clinic operators using this protocol. The evidence supporting this indication is built on three lines of applicable research:

Periarticular Soft-Tissue Pain RCT (PMC11914662)

The 2025 multicenter RCT (n=91 completers, 5 orthopedic clinics) encompassed periarticular soft-tissue pain including bursitis presentations. Patients receiving PEMF showed 36% pain reduction vs. 10% in the standard-care group (p<0.0001) and a 55% reduction in medication consumption vs. 12% in controls.

Knee Osteoarthritis Meta-Analysis (PMC9110240)

An 11-RCT meta-analysis of PEMF for knee joint pain (n=614) demonstrated pain SMD=0.71 (p=0.03), stiffness SMD=1.34 (p=0.003), and function SMD=1.52 (p=0.004). While this evidence is for osteoarthritic joint pain rather than isolated bursal inflammation, it demonstrates PEMF's ability to reduce pain and swelling in periarticular knee tissue — which is mechanistically similar to the bursal compartment.

Important context on these figures. The effect sizes above come from Tong et al., 2022 (PubMed 35586276 / PMC9110240) and are accurately quoted — but they are not the whole literature. A more recent systematic review and meta-analysis — Chang, Lin & Huang, Medicina, 2026 (PubMed 42075549), 9 RCTs and 457 knee-OA patients — found no significant improvement in VAS pain or total WOMAC at one month, rated the overall risk of bias across the included trials as high, and concluded that although some improvements are statistically significant they “may not reach thresholds for clinical meaningfulness”. Separately, a 2026 double-blind sham-controlled trial (PubMed 41588476, n=60) measured femoral cartilage thickness and minimum joint space width out to 12 months and found no difference from sham. PEMF relieves symptoms; it does not rebuild the joint. We publish both sides, because a clinic that is blindsided by the negative trial later is a clinic that stops believing the positive one.

Anti-Inflammatory Mechanism Review (PubMed 19371845)

Strauch et al. (2009) reviewed the soft-tissue anti-inflammatory mechanisms of PEMF and specifically identified collagen-producing cell stimulation, PGE2 suppression, and growth factor upregulation as primary mechanisms — all relevant to bursitis management and to prevention of the fibrosis and adhesion that can follow chronic bursal inflammation.

Clinical Protocol

Coil placement: For prepatellar and infrapatellar bursitis, the coil is positioned directly over the anterior knee with the patient supine, knee in slight flexion (10–15°). For suprapatellar or Baker's cyst presentations, a posterior-plus-anterior sandwich placement is preferred.

Combination therapy: PEMF is most effective when combined with activity modification (elimination of kneeling/impact loading during the acute phase), compression, and — in chronic cases — guided progressive loading to prevent quadriceps atrophy. Corticosteroid injection or aspiration is reserved for refractory cases with tense fluid accumulation limiting range of motion.

PEMF vs. Standard Treatments for Knee Bursitis

Contraindications

PEMF is contraindicated in septic (infectious) bursitis — which requires antibiotics and drainage — and should not be applied to areas with active malignancy. Standard PEMF contraindications also apply: active pacemaker, pregnancy, active epilepsy. Septic bursitis is typically identified by fever, skin erythema, warmth significantly greater than the contralateral knee, and laboratory markers (elevated WBC, CRP/ESR). When in doubt, aspiration for culture should precede PEMF initiation.

Who Is This For?

• Domestic workers (kasambahay) with chronic prepatellar bursitis from daily kneeling — the highest-volume subgroup in the Philippines
• Construction and manual labor workers with occupational prepatellar or infrapatellar bursitis
• Athletes in contact sports (wrestling, volleyball, basketball) with acute traumatic bursitis
• Patients with knee OA presenting with suprapatellar effusion or secondary Baker's cyst
• Post-aspiration patients where fluid has been removed but the inflammatory driver has not been addressed (preventing re-accumulation)

What This Means for Clinic Investors

Knee bursitis represents a high-volume, low-complexity clinical indication that sits at the intersection of occupational medicine and sports injury — two growing segments of the Philippine private healthcare market. The absence of any PEMF competitor in this space means early-mover advantage is meaningful. A clinic integrated into an occupational health program for a domestic staffing agency, construction company, or manufacturing employer can generate predictable, employer-subsidized patient volume with minimal marketing spend. At ₱1,500–₱2,500 per session and an 8–12 session treatment course, each patient represents ₱12,000–₱30,000 in course revenue — with high completion rates because the treatment is passive and painfree.

70+ Israeli clinics (population: 9M) have validated this model — the Philippines (population: 115M) represents a 12× market size with significantly lower treatment saturation.